Tabuk Pharmaceuticals enters into licensing and supply agreement with red otc development GmbH

One of the leading pharmaceutical companies in the Middle East and North Africa region, Tabuk Pharmaceuticals enters into licensing and supply agreement with red otc development GmbH on Ivy oro-dispersible thin films (“Ivy ODF”), red otc.

Ivy ODF is a herbal medicinal product based on ODF technology in the world. The ODF technology is one of the most recommended dosage forms by the European Medicine Agency for the treatment of pediatric population and it offers many advantages compared to syrups. It is convenient since it doesn’t need a measuring device, also it’s suitable for patients with swallowing impairments or having a high risk of aspiration.

“Working exclusively together with Tabuk, a highly esteemed and leading pharmaceutical in middle east region, is a great honor for us. We are fully convinced that our partnership with Tabuk will be extremely fruitful for the future of both companies,” commented Dr. Thomas Haffner, General Manager of red otc.